Skin; Hair; Nails; Sebaceous Glands; Cerumen Patents (Class 530/842)
  • Patent number: 7317086
    Abstract: This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the Drosophila patched (ptc) gene.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: January 8, 2008
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: Michael C. Dean, Heidi Eve Hahn, Carol Wicking, Jeffrey Christiansen, Peter G. Zaphiropoulos, Mae R. Gailani, Susan M. Shanley, Abirami Chidambaram, Igor Vorechovsky, Erika Holmberg-Lindstrom, Anne B. Unden, Susan A. Gilles, Kylie Negus, Ian McLeod Smyth, Carol L. Pressman, David J. Leffell, Bernard Gerrard, Alisa M. Goldstein, Brandon Wainwright, Rune C. M. Toftgard, Georgia Chenevix-Trench, Allen E. Bale
  • Patent number: 7001987
    Abstract: Networks, hydrogels, and methods for networks and hydrogels comprising proteinaceous material consisting essentially of water soluble proteins and covalent interprotein crosslinks other than disulfide crosslinks.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: February 21, 2006
    Assignee: Keraplast Technologies, Ltd.
    Inventor: Mark E. Van Dyke
  • Patent number: 6989437
    Abstract: Methods for producing biocompatible heterogeneous proteinaceous networks crosslinked with a heterogeneous crosslinking agent, and novel heterogeneous crosslinked networks. Preferred heterogeneous crosslinking agents are silicone-based.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: January 24, 2006
    Assignee: Keraplast Technologies, Ltd.
    Inventor: Mark E. Van Dyke
  • Patent number: 6914126
    Abstract: Methods for producing biocompatible heterogeneous proteinaceous networks crosslinked with a heterogeneous crosslinking agent, and the novel crosslinked networks.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: July 5, 2005
    Assignee: Keraplast Technologies, Ltd.
    Inventor: Mark E. Van Dyke
  • Patent number: 6841644
    Abstract: Disclosed are modified naturally occurring biocompatible biopolymers of plant and animal origin made by subjecting same to ionizing radiation in the presence of a mediating gas, typically acetylene to enable one to selectively enhance and modify one or more of the physiochemical properties of the starting materials which have a wide range of uses in medicine, food technology and other industrial applications. Notwithstanding the modifications, the biocompatibility of the biopolymer remains unchanged and no new or additional functional groups are introduced into the starting biopolymer.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: January 11, 2005
    Assignee: Phillips Hydrocolloids Research Limited
    Inventors: Glyn Owen Phillips, Tjaart Andries Du Plessis, Saphwan Al-Assaf, Peter Anthony Williams
  • Patent number: 6649740
    Abstract: A hydratable oxidized keratin composition comprising one or more metal ion species capable of absorbing water to form a hydrogel. The keratin material is useful as a soil amendment providing organic and inorganic nutrients. The keratin material is also useful as a nutrient source in the bioremediation of toxic contaminants soils and liquids.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: November 18, 2003
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Robert Allen Smith, Scott F. Timmons, Mark E. Van Dyke, Cheryl R. Blanchard, Arlene J. Siller-Jackson
  • Patent number: 6379690
    Abstract: A keratin hydrogel which can be used as a wound dressing and cell scaffolding. The keratin hydrogel is formed from clean, washed hair by partially oxidizing a significant percentage of disulfide linkages to form cysteic acid groups, while some disulfide linkages remain intact. The partially oxidized hair is treated with a reducing agent, thereby reducing most of the remaining disulfide linkages to cysteine-thioglycollate disulfide and cysteine groups. A soluble fraction of hair is collected and oxidized, such that the reduced sulfur groups are allowed to reform disulfide linkages, thereby binding the keratin together. The cysteic acid groups remain, providing hydrophilic sites within the hydrogel. A higher degree of partial oxidation results in a greater abundance of hydrophilic cysteic acid groups in the hydrogel.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 30, 2002
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Cheryl R. Blanchard, Scott F. Timmons, Robert A. Smith
  • Patent number: 6316598
    Abstract: A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. Another use for the hydrogel is as a biocompatible viscoelastic filler for implant applications.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: November 13, 2001
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Mark E. Van Dyke, Cheryl R. Blanchard, Scott F. Timmons, Arlene J. Siller-Jackson, Robert A. Smith
  • Patent number: 6165496
    Abstract: A sheet wound dressing formed of cross linked keratin. An insoluble, largely Beta keratin fraction from human hair is acidified to a low pH, preferably less than about 3, which partially solubilizes the keratin by weakening hydrogen bonds. The suspension is added to base, such as ammonium hydroxide, forming a slurry. The slurry is cast directly onto a flat surface, allowing the re-formation of cross-links including hydrogen bonds and disulfide bonds. The resulting cross-linked keratin sheet can be used as a sheet wound dressing or as a scaffolding for growth of cells. The insoluble keratin can be derived from human hair which is washed, rinsed, dried, chopped and treated with peracetic acid to break some accessible disulfide linkages. The treated hair is filtered, rinsed, dried, and ground into a keratin powder.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 26, 2000
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Scott F. Timmons, Cheryl R. Blanchard, Robert A. Smith
  • Patent number: 6159496
    Abstract: A keratin hydrogel which can be used as a wound dressing and cell scaffolding. The keratin hydrogel is formed from clean, washed hair by partially oxidizing a significant percentage of disulfide linkages to form cysteic acid groups, while some disulfide linkages remain intact. The partially oxidized hair is treated with a reducing agent, thereby reducing most of the remaining disulfide linkages to cysteine-thioglycollate disulfide and cysteine groups. A soluble fraction of hair is collected and oxidized, such that the reduced sulfur groups are allowed to reform disulfide linkages, thereby binding the keratin together. The cysteic acid groups remain, providing hydrophilic sites within the hydrogel. A higher degree of partial oxidation results in a greater abundance of hydrophilic cysteic acid groups in the hydrogel.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 12, 2000
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Cheryl R. Blanchard, Scott F. Timmons, Robert A. Smith
  • Patent number: 6124265
    Abstract: Methods for producing thin keratin films, sheets, and bulk materials, and products formed using these methods. One method includes providing hair, reducing the hair such that the disulfide linkages are broken and free cysteine thiol groups formed, separating out a more soluble keratin fraction in solution, forming a thin layer from the more soluble fraction, and air drying the keratin fraction in the presence of oxygen, thereby forming new disulfide bonds imparting strength to the resulting thin keratin film. One method includes reducing hair by heating the hair under nitrogen in an ammonium hydroxide and ammonium thioglycolate solution followed by centrifuging and collecting the supernatant containing the more soluble keratin fraction. The more soluble keratin in this method is precipitated using HCl, removed, and resuspended in ammonium hydroxide. The keratin solution thus formed is poured onto a flat surface and allowed to air dry into a thin keratin film.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: September 26, 2000
    Assignee: Keraplast Technologies, Ltd.
    Inventors: Scott F. Timmons, Cheryl R. Blanchard, Robert A. Smith
  • Patent number: 5580960
    Abstract: KS-laminin and a KS-laminin-kalinin adduct are disclosed. The molecules of the invention are useful for promoting the adhesion of keratinocytes to a substrate.
    Type: Grant
    Filed: October 22, 1993
    Date of Patent: December 3, 1996
    Assignee: The General Hospital Corporation
    Inventors: Robert E. Burgeson, Marie-France Champliaud
  • Patent number: 5567806
    Abstract: Suturable, biocompatible, control-resorbing membranes are disclosed for use in guided tissue regeneration, comprising a cross-linked collagen material either obtained by crosslinking a starting collagen material in the coagulated state produced by coagulation of a collagen material gel with a coagulating agent or obtained by crosslinking of a sponge of a collagen material on which a collagen material gel has been poured before performing the crosslinking.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 22, 1996
    Inventors: Nabil Abdul-Malak, Jean Fourcart, Alain Huc
  • Patent number: 5549904
    Abstract: A formulated biological adhesive composition utilizes tissue transglutaminase in a pharmaceutically acceptable aqueous carrier. The tissue transglutaminase is used in an effective catalytic amount to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue and/or the enzyme. The carrier contains a divalent metal ion such as calcium to promote said reaction.
    Type: Grant
    Filed: June 3, 1993
    Date of Patent: August 27, 1996
    Assignee: Orthogene, Inc.
    Inventors: Kay Juergensen, Daniel Aeschlimann, Ernst B. Hunziker
  • Patent number: 5358935
    Abstract: The present invention is a new nonantigenic keratinous protein material that may be used as a number of purposes, including correction of soft tissue deficiencies and the creation of biomedical implants and implant coatings. The present invention also includes processes for using the nonantigenic keratinous protein material for soft tissue augmentation, creating implants, and the coating of biocompatible implants. The nonantigenic keratinous protein material can be formed by obtaining nonantigenic keratinous protein and processing it to a powder form. If hair from the recipient or a compatible doner is used, it is bleached and rinsed, then dried and chopped into about 0.25 inch pieces. The keratinous protein is then homogenized in a solvent to a particular size generally in the range of about 0.1 to about 500 .mu.m. The particles are then ultrasonicated in a solvent.
    Type: Grant
    Filed: November 19, 1992
    Date of Patent: October 25, 1994
    Assignee: Robert Allen Smith
    Inventors: Robert A. Smith, Cheryl R. Blanchard, James Lankford, Jr.
  • Patent number: 5352668
    Abstract: A purified protein kalinin is disclosed that provides adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes or human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 400-460 kDa and exists in a cell-associated form (about 460 kDa) and two medium-associated forms (about 440 and 400 kDa, respectively). The cell-associated form comprises a 200-, a 155- and a 140-kDa subunit, all normally held together by disulflde bonds. The cell-associated form is subjected to extracellular processing to produce the two medium-associated forms, wherein, in the 440-kDa form, the 200-kDa subunit has been processed to a 165-kDa subunit and, in the 400-kDa form, the 155-kDa subunit has been processed to a 105-KDa subunit. The BM165 epitope is located on the 165-kDa subunit.
    Type: Grant
    Filed: August 28, 1992
    Date of Patent: October 4, 1994
    Assignee: The State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon Health Sciences University
    Inventors: Robnert E. Burgeson, Gregory P. Lunstrum, Patricia Rousselle, Douglas R. Keene, M. Peter Marinkovich
  • Patent number: 5276138
    Abstract: The present invention provides the process for treating the animal hairs by solubilization wherein the animal hairs can be treated in a short time without any complicated operations and special apparatuses, and the process for recovering the solubilized product of the animal hairs wherein said product can be recovered simply and efficiently from the solution thereof. The former is the process for treating animal hairs by solubilization which comprises solubilizing the animal hairs in a weak alkaline liquid medium in the presence of an oxidizing agent whose concentration is high. The latter is the process for recovering a solubilized product of animal hairs which comprises admixing a solution of said product with an organic acid or an aqueous solution thereof to precipitate said product.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: January 4, 1994
    Assignee: Kurashiki Boseki Kabushiki Kaisha
    Inventors: Masaru Yamada, Satoshi Narita, Takashi Kondo, Masaharu Nojima, Ryohei Yamamoto, Toyokazu Nishino, Chikaaki Sakai
  • Patent number: 5234911
    Abstract: A substance is prepared having interleukin-8 inhibiting activity by extracting psoriatic scales and separating the extract on several successive HPLC columns, using an assay for IL-8i activity based on the inhibition of myeloperoxidase release and/or of the neutrophil chemotaxis of a reference sample.The substance is suitable for the preparation of anti-inflammatory medicines.
    Type: Grant
    Filed: January 16, 1991
    Date of Patent: August 10, 1993
    Assignee: Gist-brocades, N.V.
    Inventors: Enno Christophers, Jens-Michael Schroder
  • Patent number: 5221664
    Abstract: A composition comprising a biologically active amphiphilic ion channel-forming peptide or ion channel forming protein and a toxic cation, such as a silver cation. Such compositions may be employed as pharmaceuticals, particularly for the treatment and prevention of eye infections.
    Type: Grant
    Filed: November 18, 1991
    Date of Patent: June 22, 1993
    Assignee: Magainin Pharmaaceuticals Inc.
    Inventors: Barry Berkowitz, Leonard Jacob
  • Patent number: 5102663
    Abstract: The present invention provides a vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against 9-O-acetyl GD3 ganglioside comprising an amount of purified 9-O-acetyl GD3 ganglioside effective to stimulate or enhance antibody productionThis invention was made with government support under Grant Numbers CA-40532 and CA-43971, National Cancer Institute, Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in the invention.
    Type: Grant
    Filed: October 18, 1988
    Date of Patent: April 7, 1992
    Assignee: Sloan-Kettering Instutute for Cancer Research
    Inventors: Philip O. Livingston, Gerd J. Ritter, Herbert F. Oettgen, Lloyd J. Old
  • Patent number: 5068315
    Abstract: Disclosed is a composition for regulating hair growth comprising a safe and effective amount of a polypeptide having the structure of those derived from dermal papilla cells with characteristics of apparent isoelectric pH/molecular weight selected from the group consisting of pI 5.1/45kD, pI 5.2/43kD, pI 5.2/40kD, pI 7.3/25kD, pI 7.4/25kD, or active fragment of these polypeptides, and mixtures thereof; and a pharmaceutically-acceptable carrier.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: November 26, 1991
    Assignee: University of Dundee
    Inventors: Travis E. J. Buultjens, Colin A. B. Jahoda, Roy F. Oliver
  • Patent number: 4980403
    Abstract: Collagen in tactoid form obtained by forming an aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate collagen out of solution in the form of tactoids.
    Type: Grant
    Filed: November 5, 1987
    Date of Patent: December 25, 1990
    Assignee: The University of Melbourne
    Inventors: John F. Bateman, John A. M. Ramshaw, David E. Peters, Peter A. Tulloch
  • Patent number: 4959213
    Abstract: A pharmaceutical composition for the treatment and prevention of erythma and acne comprises in a pharmaceutically acceptable carrier from about 1 to 10 weight percent based on the total weight of the composition of a delipidized and purified keratin polymer obtained from animal starting material containing keratin, the keratin polymer being in the free state.
    Type: Grant
    Filed: September 14, 1987
    Date of Patent: September 25, 1990
    Assignee: L'Oreal
    Inventors: Joel Brod, Michel Kermici
  • Patent number: 4894441
    Abstract: A process for the preparation of undenaturated triple helix collagen, starting form animal tendons or cutis, by extraction with diluted organic acids, precipitation with salts, optional gelation and/or lyophilization, tangential filtration.The obtained collagen shows favorable purity characteristics, is not allergenic and more effective in the healing processes than collagens obtained by known methods.
    Type: Grant
    Filed: March 3, 1988
    Date of Patent: January 16, 1990
    Assignee: Istituto Gentili S.p.A.
    Inventor: Claudio Menicagli
  • Patent number: 4789734
    Abstract: A method of isolating cell surface receptors utilizing a short peptide sequence bound to an affinity column. Cell surface receptors which bind selectively to the short peptide and which are specific to various adhesion proteins may be isolated therewith from various cell preparations. These receptors, whose functional integrity has been maintained by the presence of the peptide ligand, are incorporated into liposomes and used to deliver specific compounds inside the liposomes to select tissues containing the specific adhesion proteins.
    Type: Grant
    Filed: August 6, 1985
    Date of Patent: December 6, 1988
    Assignee: La Jolla Cancer Research Foundation
    Inventor: Michael D. Pierschbacher
  • Patent number: 4732891
    Abstract: Novel human placenta-derived anticoagulating substances having the following properties:(1) molecular weight of 34,000.+-.2,000 determined by SDA-polyacrylamide gel electrphoresis under reduced state;(2) isoelectric point of 4.7.+-.0.1 determined by isoelectric column electrophoresis using an ampholite;(3) stabilityinactivated by heat treatment at 50.degree. C. to 30 minutes, stable at a pH of 4-10, and stable in plasma at 37.degree. C. for 30 minutes;(4) activitycapable of prolonging a recalcification time, a prothrombin time, and an activated partial thromboplastin time; and(5) the existence of several amino acids including aspartic acid, threonine, serine, and so on; are prepared by homogenizing human placenta, subjecting the resulting homogenate to centrifugal separation, extracting an anticoagulating substance from the residue or from a microsome fraction contained in the supernatant with a surface active agent and/or a chelating agent, and purifying and isolating the substance from the extract.
    Type: Grant
    Filed: September 19, 1986
    Date of Patent: March 22, 1988
    Assignee: Kowa Co., Ltd.
    Inventors: Masahiro Maki, Hideo Tani